Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Anilides
Anilides
Antineoplastic Agents
Antineoplastic Agents
Belgium
Belgium
Female
Female
Humans
Humans
Israel
Israel
Male
Male
Melanoma
Melanoma
Middle Aged
Middle Aged
Neoplasm Metastasis
Neoplasm Metastasis
Proto-Oncogene Proteins c-met
Proto-Oncogene Proteins c-met
Pyridines
Pyridines
Receptors, Vascular Endothelial Growth Factor
Receptors, Vascular Endothelial Growth Factor
Skin Neoplasms
Skin Neoplasms
Survival Analysis
Survival Analysis
United States
United States
Uveal Neoplasms
Uveal Neoplasms
Withholding Treatment
Withholding Treatment
authors with profiles
Ali H Moussa